To request a program, click HERE.

This 60-minute program can be hosted in person or virtually in conjunction with your institution's regularly-scheduled grand rounds or tumor board meetings, and will include audience polling questions interwoven with didactic presentation. 

Overview

Given the recent approval of various CAR T-cell-based therapies for the treatment of patients with hematologic malignancies, as well as the associated volume of emerging data of both currently approved and emerging CAR T-cell therapies, it is critical that oncologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage adverse events. Thus, we propose to evaluate emerging CAR T data; and discuss the challenges of managing CAR T specific adverse events, to aid community clinicians who treat patients with lymphoma, myeloma and leukemia.

A limited number of programs are available - request yours today!

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma/myeloma/leukemia.

Learning Objectives

After participating in this activity, learners should be able to:

• Review the structure and function of CAR T-cells and the mechanism of action in patients with hematologic malignancies
• Review clinical trial data of CAR T-cell-based therapies for the treatment of patients with lymphoma, and describe where CAR T-cell therapies might fit into the treatment landscape
• Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with myeloma
• Identify characteristics of patients with acute lymphoblastic leukemia who are appropriate for treatment with CAR T-cell therapy
• Develop strategies to mitigate adverse events that may be encountered with the use of CAR T-cell therapy

Continuing Education

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education, designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Support

This activity is supported by an independent educational grant from Celgene Corporation.

Faculty Experts Available to Present at Your Institution
Julie Vose, MD, MBA (University of Nebraska Medical Center) - Course Director
Reem Karmali, MD, MS (Northwestern Feinberg School of Medicine)
Sagar Lonial, MD, FACP (Emory University Winship Cancer Institute)
Matthew Lunning, DO (University of Nebraska Medical Center) 
David Maloney, MD, PhD (Fred Hutchinson Cancer Research Center)
Noopur Raje, MD (Massachusetts General Hospital)
Nina Shah, MD (University of California, San Francisco)
 

To submit a request to host a program at your institution, click HERE.